Stocktoria
Vyome Holdings, Inc HIND
Vyome Holdings, Inc (HIND) earns a Piotroski F-score of 3/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $319,714 at a -3209.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| HIND | Vyome Holdings, Inc | 3/9 | — | — | — |
| ALLR | Allarity Therapeutics, Inc. | 3/9 | — | — | — |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | 2/9 | — | — | — |
| ABVC | ABVC BIOPHARMA, INC. | 3/9 | -13.52 | — | — |
| IBIO | iBio, Inc. | 3/9 | — | — | — |
| MNOV | MEDICINOVA INC | 1/9 | -18.54 | — | — |
| SCNX | Scienture Holdings, Inc. | 4/9 | -0.88 | — | — |
About Vyome Holdings, Inc
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop is an inosine 5'-monophosphate dehydrogenase enzyme inhibitor to treat immunoinflammatory conditions of the eye; and VB-1953, which is in phase 2 clinical stage for the treatment of inflammatory acne. In addition, the company develops antifungal products using the molecular replacement therapy (MRT) platform. It has a collaboration and license agreement with Sun Pharma Laboratories Limited to develop and commercialize next-generation antifungal products. The company is based in Cambridge, Massachusetts.
FAQ
Is HIND financially healthy?
Vyome Holdings, Inc's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak).
Does HIND pay a dividend?
No, Vyome Holdings, Inc does not currently pay a dividend.
How profitable is HIND?
In FY2025, Vyome Holdings, Inc had a net margin of -3209.7% and a return on equity of -272.8%.
What is the analyst price target for HIND?
The average Wall-Street price target for Vyome Holdings, Inc is $11.50, about 418.0% above the recent price, from 2 analysts.
Is HIND a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Vyome Holdings, Inc: a Piotroski F-score of 3/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.